{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:47:47Z","timestamp":1782712067802,"version":"3.54.5"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Coagulation activation and tumor hemorrhage are common in colorectal cancer, but their combined immunological meaning remains incompletely defined. We developed a prespecified hemorrhage-coagulation immune phenotype (HCIP) integrating local hemorrhagic pathology and systemic coagulation activation, and evaluated its association with recurrence-free survival (RFS), CD163\/HO-1-enriched immune remodeling, and incremental prognostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients who underwent radical resection for colorectal adenocarcinoma at The First People\u2019s Hospital of Jiashan County between January 2016 and December 2025. HCIP was defined from a local hemorrhagic axis, based on H&amp;amp;E-assessed intratumoral hemorrhage and hemosiderin\/Prussian blue evidence, and a systemic coagulation axis, based on preoperative fibrinogen, D-dimer, and platelet count. The primary outcome was RFS. A balanced FFPE subset was used for exploratory immunohistochemical assessment of CD8, CD68, CD163, HO-1, fibrinogen\/fibrin, and tissue factor. Cox models, prespecified sensitivity analyses, and validation-cohort prediction analyses with bootstrap uncertainty estimates were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The final analytic cohort included 752 patients. HCIP-poor tumors were enriched for advanced AJCC stage, larger tumor size, ulceration, and necrosis. In the balanced FFPE subset, HCIP-poor tumors showed lower CD8+ stromal T-cell density, higher CD163+ macrophage density, stronger HO-1, fibrinogen\/fibrin, and tissue factor staining, a lower CD8\/CD163 ratio, and a higher macrophage-heme-coagulation score. In multivariable Cox analysis, HCIP-poor status was associated with worse RFS (adjusted HR 1.91, 95% CI 1.33-2.73). The association remained directionally consistent in stage II\/III-only, T\/N-stage-adjusted, MSI\/MMR-stratified, IPTW, and recurrence-only sensitivity analyses. Among individual hemorrhage\/coagulation components, fibrinogen was the most stable marker associated with RFS. In the validation cohort, adding fibrinogen, HCIP, or hemorrhage\/coagulation components produced modest incremental discrimination and lower prediction error beyond clinical variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>HCIP identifies a clinically accessible hemorrhage-coagulation state associated with CD163\/HO-1-enriched heme-processing macrophage features and coagulation-associated immune remodeling in colorectal cancer. Fibrinogen remained the most practical single coagulation marker, whereas HCIP provided a biologically interpretable composite phenotype linking local hemorrhagic pathology, systemic coagulation activation, and recurrence risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1868145","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:39:13Z","timestamp":1782711553000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hemorrhage-coagulation immune phenotype is associated with CD163\/HO-1-enriched heme-processing macrophage remodeling and predicts recurrence in colorectal cancer: a real-world retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Yiqi","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The First People\u2019s Hospital of Jiashan County","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First People\u2019s Hospital of Jiashan County","place":["Jiaxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01221-0","article-title":"Colorectal cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pages","year":"2018","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.724429","article-title":"The ratio of CD86+\/CD163+ macrophages predicts postoperative recurrence in stage II-III colorectal cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246166","article-title":"CD163 as a potential biomarker in colorectal cancer for tumor microenvironment and cancer prognosis: a Swedish study from tissue microarrays to big data analyses","volume":"14","author":"Ma","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1042\/bsr20130057","article-title":"Activation of blood coagulation in cancer: implications for tumour progression","volume":"33","author":"Lima","year":"2013","journal-title":"Biosci Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.12.008","article-title":"Coagulome and the tumor microenvironment: an actionable interplay","volume":"8","author":"Galmiche","year":"2022","journal-title":"Trends Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.07.052","article-title":"Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: a systematic review and meta-analysis","volume":"44","author":"Lin","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000016974","article-title":"Prognostic value of pretreatment plasma fibrinogen in patients with colorectal cancer: a systematic review and meta-analysis","volume":"98","author":"Li","year":"2019","journal-title":"Med (Balt)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1161\/atvbaha.108.177428","article-title":"Tissue factor and PAR2 signaling in the tumor microenvironment","volume":"29","author":"Schaffner","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215983","article-title":"Tissue factor-induced fibrinogenesis mediates cancer cell clustering and multiclonal peritoneal metastasis","volume":"553","author":"Miyazaki","year":"2023","journal-title":"Cancer Lett"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051524","article-title":"The tissue factor pathway in cancer: overview and role of heparan sulfate proteoglycans","volume":"15","author":"Hassan","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2012.4834","article-title":"CD163 and inflammation: biological, diagnostic, and therapeutic aspects","volume":"18","author":"Etzerodt","year":"2013","journal-title":"Antioxid Redox Signal"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/523652","article-title":"The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging","volume":"2013","author":"Thomsen","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2022.08.005","article-title":"Erythrophagocytes in hemolytic anemia, wound healing, atherosclerosis, and cancer","volume":"28","author":"Schaer","year":"2022","journal-title":"Trends Mol Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3","article-title":"The lasso method for variable selection in the Cox model","volume":"16","author":"Tibshirani","year":"1997","journal-title":"Stat Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v039.i05","article-title":"Regularization paths for Cox's proportional hazards model via coordinate descent","volume":"39","author":"Simon","year":"2011","journal-title":"J Stat Softw"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1201\/9781003493679-19","article-title":"Random survival forests","volume":"2","author":"Ishwaran","year":"2008","journal-title":"Ann Appl Stat"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341x.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.114.014508","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD)","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.10.002","article-title":"Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis","volume":"41","author":"Perisanidis","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.115027","article-title":"The role of coagulome in the tumor immune microenvironment","volume":"200","author":"Wahab","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1393599","article-title":"Fibrinogen and tumors","volume":"14","author":"Wu","year":"2024","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.01.031","article-title":"Tumor-associated macrophages","volume":"30","author":"Cassetta","year":"2020","journal-title":"Curr Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12307-014-0145-7","article-title":"Macrophage infiltration in tumor stroma is related to tumor cell CD163 expression and clinical outcome in colorectal cancer","volume":"5","author":"Shabo","year":"2014","journal-title":"J Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1042395","DOI":"10.3390\/cancers14246166","article-title":"CD163 as a potential biomarker in colorectal cancer","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-16399-0","volume-title":"Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating","author":"Steyerberg","year":"2019"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1868145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T05:39:14Z","timestamp":1782711554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1868145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1868145"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1868145","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"article-number":"1868145"}}